IL6 and familial pancreatic carcinoma: Numerous investigations have underscored the connection between increased IL-6 expression and a worse prognosis, as well as chemotherapy resistance, in patients with pancreatic cancer, non-small cell lung cancer (NSCLC), ovarian cancer, and other malignancies (7–10).